Cetera Investment Advisers’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-171,428
Closed -$2.59M 3829
2024
Q3
$2.59M Buy
171,428
+15,044
+10% +$228K 0.01% 1427
2024
Q2
$2.22M Buy
156,384
+10,137
+7% +$137K 0.01% 1486
2024
Q1
$1.99M Buy
146,247
+10,979
+8% +$152K ﹤0.01% 1546
2023
Q4
$1.82M Buy
135,268
+18,268
+16% +$225K 0.01% 836
2023
Q3
$1.46M Buy
117,000
+11,107
+10% +$146K 0.01% 882
2023
Q2
$1.43M Buy
105,893
+13,093
+14% +$181K 0.01% 918
2023
Q1
$1.29M Buy
92,800
+13,123
+16% +$188K 0.01% 924
2022
Q4
$1.13M Buy
79,677
+13,915
+21% +$202K 0.01% 942
2022
Q3
$898K Buy
65,762
+6,907
+12% +$103K 0.02% 765
2022
Q2
$838K Buy
58,855
+11,527
+24% +$174K 0.01% 865
2022
Q1
$783K Sell
47,328
-630
-1% -$10.8K 0.01% 906
2021
Q4
$922K Sell
47,958
-71,259
-60% -$1.43M 0.01% 839
2021
Q3
$2.48M Sell
119,217
-15,960
-12% -$342K 0.04% 448
2021
Q2
$2.9M Buy
135,177
+3,623
+3% +$73.1K 0.05% 410
2021
Q1
$2.59M Buy
131,554
+35,957
+38% +$741K 0.05% 362
2020
Q4
$1.89M Buy
+95,597
New +$1.77M 0.04% 446

Other funds holding HQL

Cetera Investment Advisers's HQL Position: Q4 2024 in Review

Cetera Investment Advisers sold out of abrdn Life Sciences Investors (HQL) in Q4 2024, closing a stake of 171,428 shares — an estimated $2.59M sold.

Cetera Investment Advisers first reported a position in HQL in Q4 2020 and held it in 16 quarters. The position peaked at $2.9M in Q2 2021. 72 funds tracked by Wall St. Rank hold HQL as of Q4 2024.

  • Cetera Investment Advisers reported no remaining abrdn Life Sciences Investors position as of Q4 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 171,428 abrdn Life Sciences Investors shares in Q4 2024, an estimated $2.59M.
  • Cetera Investment Advisers first reported a position in abrdn Life Sciences Investors in Q4 2020 and held it in 16 quarters.
  • Cetera Investment Advisers's abrdn Life Sciences Investors position peaked at $2.9M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2024.

Based on Cetera Investment Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.